Pharmacokinetics of oral amlodipine orotate in vagotomized dogs
โ Scribed by Hyun H. Kwak; Jong O. Kim; Han K. Chung; Seul M. Choi; Jung H. Kim; Jong W. Kwon; Moohi Yoo; Joo H. Lee; Myung G. Lee
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 77 KB
- Volume
- 27
- Category
- Article
- ISSN
- 0142-2782
- DOI
- 10.1002/bdd.495
No coin nor oath required. For personal study only.
โฆ Synopsis
It was reported that gastric motility was delayed and gastric acid secretion was reduced in vagotomized dogs which mimics a low gastric acidity in humans. A delay in gastric motility causes long residence of amlodipine in the stomach. More unionized fractions of amlodipine could exist in less acidic conditions of gastrointestinal fluids, since amlodipine is a weak basic drug with pKa of 8.7. Hence, gastrointestinal absorption of amlodipine is expected to be enhanced and the time to reach a peak plasma concentration of amlodipine (T max ) is faster in vagotomized dogs. This was proven after oral administration of an amlodipine orotate tablet at a dose of 5 mg as amlodipine in vagotomized dogs. For example, in vagotomized dogs, the total area under the plasma concentration-time curve from time zero to the last measured time, 48 h, in plasma (AUC 0-48 h ) was significantly greater (725 versus 348 ng h/ml) and T max was significantly shorter (1.50 versus 5.00 h) than those in dogs without vagotomy.
๐ SIMILAR VOLUMES
An adaption of a published high performance liquid chromatographic (HPLC) assay for phenylpropanolamine (PPA) in plasma was used to examine PPA pharmacokinetics in dogs. Plasma was extracted into ethyl acetate after the addition of 3.5 per cent sodium carbonate, and was then back-extracted into aque
The pharmacokinetics of total and free tiazofurin, an antineoplastic agent, was studied in healthy mongrel dogs following intravenous and oral administration of the drug. The free fraction of tiazofurin was obtained from plasma by an ultrafiltration technique using a micropartition system. Total and
The pharmacokinetics of a new serotonin 5-HT 2 antagonist, deramciclane, was studied. Single oral doses of 1, 3, 6 and 10 mg kg -1 and intravenous doses of 1, 3 and 6 mg kg -1 were administered in beagle dogs. Moreover, the steady state pharmacokinetics of 1, 3 and 6 mg kg -1 doses were studied. Der